RAPT Therapeutics, Inc. (RAPT) Stock Analysis
DELISTED 2026
What happened to RAPT Therapeutics, Inc. (RAPT) stock?
RAPT Therapeutics, Inc. (RAPT) no longer trades on public markets. It was delisted in March 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RAPT Therapeutics, Inc. (RAPT) trades at $58.01. RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule therapies for oncology and inflammatory diseases. Market cap: $959M, Sector: Healthcare.
Last analyzed: May 9, 2026RAPT stock analysis for 2026: Analysts have set a consensus price target of $64.17 for RAPT Therapeutics, Inc., suggesting 10.6% upside from the current price of $58.01. Key factors: analyst coverage, company fundamentals.
RAPT: 2/2 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →RAPT Therapeutics, Inc. (RAPT) Healthcare & Pipeline Overview
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company specializing in oral small molecule therapies for oncology and inflammatory diseases. Their focus on CCR4 antagonism differentiates them within the competitive biotechnology landscape, addressing unmet needs in targeted immune modulation.
What Is the Investment Thesis for RAPT?
RAPT Therapeutics, Inc. presents a notable research candidate based on its innovative approach to modulating immune responses in oncology and inflammatory diseases. The company's lead drug candidates, RPT193 and FLX475, target CCR4, a key chemokine receptor involved in the migration of immune cells to inflamed tissues and tumors. Positive clinical data from ongoing trials of RPT193 in inflammatory diseases and FLX475 in advanced cancers could serve as significant catalysts for the stock. Key value drivers include successful completion of Phase 2 trials for RPT193, demonstrating efficacy and safety, and advancement of FLX475 through Phase 2 trials, showing synergistic effects in combination with pembrolizumab. The company's market capitalization of $959M, combined with its focus on oral small molecule therapies, positions it favorably within the biotechnology sector. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's ability to secure partnerships and funding will also be crucial for long-term success.
Based on FMP financials and quantitative analysis
RAPT Key Highlights
RAPT Therapeutics focuses on oral small molecule therapies, offering potential advantages in patient convenience and accessibility.
- Lead drug candidate RPT193 targets CCR4 to inhibit the migration of type 2 T helper cells into inflamed tissues, addressing inflammatory diseases.
- Lead oncology drug candidate FLX475, also a CCR4 antagonist, is in Phase 1/2 clinical trials as a monotherapy and in combination with pembrolizumab for advanced cancer.
- The company changed its name from FLX Bio, Inc. to RAPT Therapeutics, Inc. in May 2019, reflecting a strategic shift.
- RAPT Therapeutics has a market capitalization of $959M and employs 67 people, indicating a focused and agile operation.
Who Are RAPT's Competitors?
RAPT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALMS Alumis Inc. | $22.86 | -4.71% | $2.82B | — |
| CLYM Climb Bio, Inc. | $17.02 | -1.85% | $975M | 76 |
| ABUS Arbutus Biopharma Corporation | $4.77 | -4.22% | $942M | 83 |
| VERV Verve Therapeutics, Inc. | $11.13 | +0.27% | $994M | 71 |
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $916M | 71 |
| TBPH Theravance Biopharma, Inc. | $16.95 | -0.24% | $878M | 95 |
| CVAC CureVac N.V. | $4.66 | +0.00% | $1.05B | 71 |
| RIGL Rigel Pharmaceuticals, Inc. | $45.09 | -3.97% | $834M | 84 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RAPT's Key Strengths?
Proprietary drug candidates targeting CCR4.
- Expertise in immunology and oral small molecule therapies.
- Clinical-stage pipeline with potential for near-term catalysts.
- Experienced management team with a track record in drug development.
What Are RAPT's Weaknesses?
Reliance on clinical trial outcomes, which are inherently uncertain.
- Limited financial resources compared to larger pharmaceutical companies.
- Dependence on partnerships for commercialization.
- High research and development costs.
What Could Drive RAPT Stock Higher?
Phase 2 clinical trial data readout for RPT193 in inflammatory diseases.
- Phase 1/2 clinical trial results for FLX475 in combination with pembrolizumab.
- Enrollment and progress in ongoing clinical trials for RPT193 and FLX475.
- Potential for new partnerships or collaborations to fund development programs.
What Are the Key Risks for RAPT?
Negative return on equity (-61.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for RPT193 or FLX475.
- Regulatory delays or rejection of drug candidates.
- Competition from established pharmaceutical companies with greater resources.
- Dependence on securing additional funding to support clinical development.
- Patent challenges or infringement claims.
What Are the Growth Opportunities for RAPT?
- Advancement of RPT193 in Inflammatory Diseases: RAPT Therapeutics has a significant growth opportunity in advancing RPT193, its lead inflammation drug candidate, through clinical trials. The market for inflammatory disease therapies is substantial, estimated at billions of dollars annually. Successful Phase 2 trials demonstrating efficacy in specific inflammatory conditions could lead to partnerships or eventual commercialization, driving revenue growth. The timeline for this growth opportunity is dependent on clinical trial progress, with potential for initial data readouts within the next 12-18 months.
- Expansion of FLX475 in Oncology: The development of FLX475, RAPT's lead oncology drug candidate, represents another key growth opportunity. The global oncology market is vast and growing, with a high demand for novel therapies. Positive results from the ongoing Phase 1/2 clinical trial, particularly in combination with pembrolizumab, could position FLX475 as a valuable treatment option for advanced cancers. This growth opportunity is contingent on clinical trial outcomes and regulatory approvals, with potential for significant market impact in the next 3-5 years.
- Development of Hematopoietic Progenitor Kinase 1 Inhibitor: RAPT's focus on developing a hematopoietic progenitor kinase 1 inhibitor presents a longer-term growth opportunity. This novel target could address unmet needs in various diseases, potentially expanding the company's therapeutic pipeline. The market for kinase inhibitors is well-established, with numerous approved drugs generating substantial revenue. Success in this area would require significant research and development efforts, with potential for clinical trials to begin in the next 2-3 years.
- Strategic Partnerships and Collaborations: RAPT Therapeutics can drive growth through strategic partnerships and collaborations with larger pharmaceutical companies. These partnerships can provide funding, expertise, and access to larger markets. The biotechnology industry is characterized by frequent collaborations, with companies often partnering to develop and commercialize new therapies. Securing a significant partnership within the next 12-24 months could accelerate the development and commercialization of RAPT's pipeline.
- Expansion of Pipeline through Internal Discovery: RAPT Therapeutics can leverage its expertise in immunology to expand its pipeline through internal drug discovery efforts. Identifying and developing new drug candidates targeting novel immune pathways can create long-term growth opportunities. The company's research and development capabilities, combined with its focus on oral small molecule therapies, position it well to pursue this strategy. This growth opportunity is dependent on ongoing research and development investments, with potential for new drug candidates to enter clinical trials in the next 3-5 years.
What Are RAPT's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Expertise in immunology and drug development.
- Focus on oral small molecule therapies, offering convenience and accessibility.
- Targeting CCR4, a validated target in oncology and inflammatory diseases.
What Does RAPT Do?
RAPT Therapeutics, Inc., founded in 2015 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing oral small molecule therapies for patients grappling with oncology and inflammatory diseases. Originally incorporated as FLX Bio, Inc., the company rebranded as RAPT Therapeutics, Inc. in May 2019, marking a strategic shift towards its current focus. RAPT's pipeline is built on its expertise in immunology and the development of targeted therapies that modulate immune responses. The company's lead inflammation drug candidate, RPT193, is a C-C motif chemokine receptor 4 (CCR4) antagonist. RPT193 selectively inhibits the migration of type 2 T helper cells into inflamed tissues, aiming to address the underlying causes of inflammatory diseases. RAPT's lead oncology drug candidate, FLX475, is also an oral small molecule CCR4 antagonist. FLX475 is currently undergoing a Phase 1/2 clinical trial, both as a monotherapy and in combination with pembrolizumab, to assess its efficacy in patients with advanced cancer. The company is also invested in the development of a hematopoietic progenitor kinase 1 inhibitor, expanding its therapeutic reach. RAPT Therapeutics operates with a team of 67 employees, focusing on rigorous scientific research and clinical development to bring innovative therapies to market. The company's strategic focus on oral small molecule therapies provides a potential advantage in terms of patient convenience and accessibility compared to injectable biologics. By targeting CCR4, RAPT aims to address a critical pathway in both oncology and inflammatory diseases, offering a novel approach to treatment.
What Products and Services Does RAPT Offer?
- Discovers and develops oral small molecule therapies.
- Focuses on immunology-based treatments.
- Targets oncology and inflammatory diseases.
- Develops CCR4 antagonists to modulate immune responses.
- Conducts clinical trials to evaluate drug candidates.
- Seeks to commercialize innovative therapies for unmet medical needs.
How Does RAPT Make Money?
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical trials to demonstrate efficacy and safety.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
What Industry Does RAPT Operate In?
The biotechnology industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. RAPT Therapeutics operates in this dynamic environment, focusing on immunology-based therapies for oncology and inflammatory diseases. The market for these therapies is substantial, driven by the increasing prevalence of cancer and autoimmune disorders. The company's focus on oral small molecule therapies provides a competitive edge, offering potential advantages over injectable biologics. Competitors like ALMS: Alumis Inc. are also developing therapies in the immunology space, highlighting the growing interest and investment in this area. The success of RAPT Therapeutics will depend on its ability to navigate the regulatory landscape, secure funding, and demonstrate clinical efficacy.
Who Are RAPT's Key Customers?
- Patients with cancer.
- Patients with inflammatory diseases.
- Pharmaceutical companies seeking to license or acquire novel therapies.
- Healthcare providers prescribing treatments for cancer and inflammatory conditions.
Forward Outlook
Wall Street analysts project RAPT Therapeutics, Inc. revenue of about $10.2M for fiscal 2026, with EPS near $-3.17. The estimate reflects 4 contributing analysts.
RAPT Valuation & Market Position
With a $959M market cap, RAPT Therapeutics, Inc. sits in the small-cap segment of the market.
Key Financial Metrics
Return on equity for RAPT Therapeutics, Inc. stands at -61.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -63.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -9.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
RAPT Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 35.15 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
RAPT Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Brian Russell Wong. RAPT has traded publicly since 2019.
RAPT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- RAPT Therapeutics has seen positive insider activity recently, suggesting confidence from leadership in the company's direction.
- Community sentiment has been increasingly optimistic, with discussions highlighting the potential of their drug pipeline.
- Recent clinical trial updates have sparked excitement among investors, reinforcing belief in the company's innovative approach.
- Collaborations with prominent research institutions have enhanced RAPT's credibility and visibility in the biotech sector.
Bear Case
- Despite bullish sentiment, some analysts express concern over RAPT's long-term profitability given the competitive landscape in therapeutics.
- There have been discussions in the community about the risks associated with regulatory approvals, which could impact timelines.
- Market perception remains cautious, with some investors worried about the company's cash burn rate amid ongoing research and development.
- Recent volatility in biotech stocks has led to broader skepticism, with RAPT being viewed as potentially vulnerable to market shifts.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RAPT Latest News
No recent news available for RAPT.
Leadership: Brian Russell Wong
CEO
Brian Russell Wong serves as the CEO of RAPT Therapeutics, Inc. His career spans leadership roles in multiple biotechnology firms, bringing extensive experience in corporate strategy, business development, and financial management. Prior to RAPT, Wong held executive positions at various pharmaceutical companies, contributing to drug development and commercialization efforts. He holds advanced degrees in both science and business, providing a strong foundation for leading a clinical-stage biopharmaceutical company.
Track Record: Under Brian Russell Wong's leadership, RAPT Therapeutics has advanced its lead drug candidates, RPT193 and FLX475, through clinical trials. He has overseen strategic partnerships and funding initiatives to support the company's growth. Wong has also guided the company through key milestones, including the transition from FLX Bio to RAPT Therapeutics and the expansion of its therapeutic pipeline.
What Investors Ask About RAPT Therapeutics, Inc. (RAPT) — Healthcare
What happened to RAPT Therapeutics, Inc. (RAPT) stock?
RAPT Therapeutics, Inc. (RAPT) no longer trades on public markets. It was delisted in March 2026. The figures below are historical and are not a current quote.
Can I still buy RAPT shares?
No. RAPT stopped trading on public markets in March 2026, so the shares are not available through a broker. Anything you see quoted for RAPT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before RAPT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to RAPT Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does RAPT Therapeutics, Inc. do?
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Their lead drug candidates, RPT193 and FLX475, are CCR4 antagonists designed to selectively inhibit the migration of immune cells into inflamed tissues and tumors.
What do analysts say about RAPT stock?
Analyst coverage of RAPT Therapeutics, Inc. typically focuses on the potential of its lead drug candidates, RPT193 and FLX475, and the progress of their clinical trials. Key valuation metrics include the company's market capitalization, cash runway, and potential revenue from future commercialization. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and the ability to secure partnerships.
What are the main risks for RAPT?
The main risks for RAPT Therapeutics, Inc. include the inherent uncertainties of clinical drug development, such as the potential for clinical trial failures or unexpected safety issues. Regulatory hurdles and delays in obtaining approvals from the FDA or other regulatory agencies also pose significant risks.
How does RAPT Therapeutics, Inc. navigate regulatory approval processes?
RAPT Therapeutics, Inc. navigates regulatory approval processes by adhering to stringent guidelines set by regulatory agencies such as the FDA. This involves conducting comprehensive preclinical studies to establish safety and efficacy, followed by well-designed clinical trials. The company maintains open communication with regulatory bodies, seeking guidance and feedback throughout the development process.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Clinical trial outcomes are inherently uncertain and may impact the company's future performance.